Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Imugene ( (AU:IMU) ) has issued an update.
Imugene has requested an immediate trading halt in its securities on the ASX as it prepares to announce a proposed capital raising. The halt, granted under ASX Listing Rule 17.1, will remain in place until the capital-raising announcement is released or until normal trading resumes on 12 March 2026, signalling an imminent move to secure additional funding that could influence its operational capacity and investor positioning.
The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.21 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is an Australian biotechnology company listed on the ASX under the ticker IMU. The company focuses on developing immuno-oncology therapies, aiming to harness the immune system to treat cancer and improve patient outcomes in global healthcare markets.
YTD Price Performance: -35.62%
Average Trading Volume: 1,403,619
Technical Sentiment Signal: Sell
Current Market Cap: A$75.56M
Find detailed analytics on IMU stock on TipRanks’ Stock Analysis page.